van Rhee F on Muck Rack

van Rhee F

As seen in: Ash Publications
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with van Rhee

Contact van Rhee, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Under-Representation of Black Patients with Multiple Myeloma in Studies Supporting International Myeloma Working Group Guidelines

|
By Shaughnessy JD, van Rhee F, Hadidi SA
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (555) Issue with article?

Acquired hemophilia A (AHA) due to anti-SARS-CoV-2 vaccination: A systematic review

|
By van Rhee F
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (637) Issue with article?

van Rhee F, Rosenthal A, Kanhai K, et al. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv. 2022;6(16):4773-4781. | Blood Advances | American Society of Hematology

|
By van Rhee F
| Ash Publications
In this study, the authors conducted a post hoc analysis of the data from the 2014 phase 2 study of siltuximab in idiopathic multicentric Castleman disease (iMCD),1 the purpose being to better inform clinicians about the benefits of siltuximab. After publication, it came to the authors’ attention that progression-free survival (PFS) was defined differently in the Methods section of the article than in the Results section.
Open in Who Shared Issue with article?
See all 4 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with van Rhee

Contact van Rhee, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified